Moleculin Biotech is a clinical-stage company developing Annamycin (naxtarubicin), an anthracycline designed to avoid heart damage, for relapsed or refractory acute myeloid leukemia; it is not approved.
Moleculin's case rests on Annamycin plus cytarabine for second-line relapsed or refractory AML. Interim complete remission rates were 43% and 36% versus 12% for control. All 90 Part A patients have now been treated, with comprehensive results expected in Q1 2027 to guide Part B dosing. Management expects cash, including $9.3 million raised after quarter-end, to support operations into the first quarter of 2027. Further trial financing remains necessary and uncommitted, leaving clinical differentiation and funding central to the investment case.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Full Part A data confirm the remission advantage
Does Annamycin retain a clear remission advantage over control in the full 90-patient population, including patients previously treated with venetoclax?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
MIRACLE Part A dosing complete; results and funding remain pivotal
Phase 3 interim shows 3x CR advantage in R/R AML, but cash runs out before Part A unblinding — survival to data is the entire bet
MIRACLE interim shows 3x CR rate over control, but cash expires before Part B data lands
Annamycin's 40% CRc signal in R/R AML drives accelerated approval pursuit, contingent on Part A unblinding confirming efficacy and financing survival
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.